Interpretation of serial interferon-gamma test results to measure new tuberculosis infection among household contacts in Zambia and South Africa.
Conversion
Interferon-gamma
QuantiFERON
Tuberculosis
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
15 Oct 2020
15 Oct 2020
Historique:
received:
13
04
2020
accepted:
06
10
2020
entrez:
16
10
2020
pubmed:
17
10
2020
medline:
13
11
2020
Statut:
epublish
Résumé
A more stringent QuantiFERON-TB Gold In-Tube (QFT) conversion (from negative to positive) definition has been proposed to allow more definite detection of recent tuberculosis (TB) infection. We explored alternative conversion definitions to assist the interpretation of serial QFT results and estimate incidence of TB infection in a large cohort study. We used QFT serial results from TB household contacts aged ≥15 years, collected at baseline and during two follow-up visits (2006-2011) as part of a cohort study in 24 communities in Zambia and South Africa (SA). Conversion rates using the manufacturers' definition (interferon-gamma (IFN-g) < 0.35 to ≥0.35, 'def1') were compared with stricter definitions (IFN-g < 0.2 to ≥0.7 IU/ml, 'def2'; IFN-g < 0.2 to ≥1.05 IU/ml, 'def3'; IFN-g < 0.2 to ≥1.4 IU/ml, 'def4'). Poisson regression was used for analysis. One thousand three hundred sixty-five individuals in Zambia and 822 in SA had QFT results available. Among HIV-negative individuals, the QFT conversion rate was 27.4 per 100 person-years (CI:22.9-32.6) using def1, 19.0 using def2 (CI:15.2-23.7), 14.7 using def3 (CI:11.5-18.8), and 12.0 using def4 (CI:9.2-15.7). Relative differences across def1-def4 were similar in Zambia and SA. Using def1, conversion was less likely if HIV positive not on antiretroviral treatment compared to HIV negative (aRR = 0.7, 95%CI = 0.4-0.9), in analysis including both countries. The same direction of associations were found using def 2-4. High conversion rates were found even with the strictest definition, indicating high incidence of TB infection among household contacts of TB patients in these communities. The trade-off between sensitivity and specificity using different thresholds of QFT conversion remains unknown due to the absence of a reference standard. However, we identified boundaries within which an appropriate definition might fall, and our strictest definition plausibly has high specificity.
Sections du résumé
BACKGROUND
BACKGROUND
A more stringent QuantiFERON-TB Gold In-Tube (QFT) conversion (from negative to positive) definition has been proposed to allow more definite detection of recent tuberculosis (TB) infection. We explored alternative conversion definitions to assist the interpretation of serial QFT results and estimate incidence of TB infection in a large cohort study.
METHODS
METHODS
We used QFT serial results from TB household contacts aged ≥15 years, collected at baseline and during two follow-up visits (2006-2011) as part of a cohort study in 24 communities in Zambia and South Africa (SA). Conversion rates using the manufacturers' definition (interferon-gamma (IFN-g) < 0.35 to ≥0.35, 'def1') were compared with stricter definitions (IFN-g < 0.2 to ≥0.7 IU/ml, 'def2'; IFN-g < 0.2 to ≥1.05 IU/ml, 'def3'; IFN-g < 0.2 to ≥1.4 IU/ml, 'def4'). Poisson regression was used for analysis.
RESULTS
RESULTS
One thousand three hundred sixty-five individuals in Zambia and 822 in SA had QFT results available. Among HIV-negative individuals, the QFT conversion rate was 27.4 per 100 person-years (CI:22.9-32.6) using def1, 19.0 using def2 (CI:15.2-23.7), 14.7 using def3 (CI:11.5-18.8), and 12.0 using def4 (CI:9.2-15.7). Relative differences across def1-def4 were similar in Zambia and SA. Using def1, conversion was less likely if HIV positive not on antiretroviral treatment compared to HIV negative (aRR = 0.7, 95%CI = 0.4-0.9), in analysis including both countries. The same direction of associations were found using def 2-4.
CONCLUSION
CONCLUSIONS
High conversion rates were found even with the strictest definition, indicating high incidence of TB infection among household contacts of TB patients in these communities. The trade-off between sensitivity and specificity using different thresholds of QFT conversion remains unknown due to the absence of a reference standard. However, we identified boundaries within which an appropriate definition might fall, and our strictest definition plausibly has high specificity.
Identifiants
pubmed: 33059620
doi: 10.1186/s12879-020-05483-9
pii: 10.1186/s12879-020-05483-9
pmc: PMC7559914
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
760Subventions
Organisme : Medical Research Council
ID : MR/N020618/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Organisme : European and Developing Countries Clinical Trials Partnership
ID : MR/R010161/1
Organisme : Johns Hopkins University
ID : 19790.01
Références
Int J Tuberc Lung Dis. 2003 May;7(5):426-31
pubmed: 12757042
Am J Respir Crit Care Med. 2009 Jul 1;180(1):49-58
pubmed: 19342414
J Occup Med Toxicol. 2012 Jun 18;7(1):6
pubmed: 22537915
Lancet. 2013 Oct 5;382(9899):1183-94
pubmed: 23915882
N Engl J Med. 2015 May 28;372(22):2127-35
pubmed: 26017823
Clin Infect Dis. 2008 Aug 1;47(3):349-55
pubmed: 18558885
J Clin Microbiol. 2016 Apr;54(4):845-50
pubmed: 26763969
PLoS One. 2009 Nov 13;4(11):e7749
pubmed: 19915666
Am J Respir Crit Care Med. 2012 Nov 15;186(10):1051-6
pubmed: 22955316
Chest. 2012 Dec;142(6):1366-1368
pubmed: 23208326
Int J Tuberc Lung Dis. 2017 Jun 1;21(6):690-696
pubmed: 28482964
PLoS One. 2011 Apr 04;6(4):e18206
pubmed: 21483746
Am J Respir Crit Care Med. 2017 Sep 1;196(5):638-648
pubmed: 28737960
Am J Respir Crit Care Med. 2006 Aug 1;174(3):349-55
pubmed: 16690977
Ann Am Thorac Soc. 2014 Mar;11(3):296-302
pubmed: 24446969
Proc Biol Sci. 1999 Apr 22;266(1421):859-67
pubmed: 10343409
PLoS One. 2014 Dec 26;9(12):e115322
pubmed: 25541947
Am J Respir Crit Care Med. 2014 Nov 15;190(10):1168-76
pubmed: 25303140
Clin Microbiol Infect. 2016 Aug;22(8):701-3
pubmed: 27184875
MMWR Recomm Rep. 2005 Dec 16;54(RR-15):49-55
pubmed: 16357824
Lancet. 2004 Jan 17;363(9404):212-4
pubmed: 14738796
PLoS One. 2008 Mar 26;3(3):e1850
pubmed: 18365006
J Clin Microbiol. 2018 Jun 25;56(7):
pubmed: 29743310
J Clin Microbiol. 2009 May;47(5):1338-43
pubmed: 19261801
Am J Respir Crit Care Med. 2013 Jan 15;187(2):206-11
pubmed: 23103734
Tuber Lung Dis. 1996 Jun;77 Suppl 1:1-19
pubmed: 8759471
Am J Respir Crit Care Med. 2014 Jan 1;189(1):77-87
pubmed: 24299555
Am J Epidemiol. 2011 Dec 1;174(11):1246-55
pubmed: 22071585
Int J Tuberc Lung Dis. 2017 Nov 1;21(11):49-59
pubmed: 29025485
Lancet Infect Dis. 2012 Jan;12(1):45-55
pubmed: 21846592
Clin Microbiol Rev. 2014 Jan;27(1):3-20
pubmed: 24396134
J Immunol. 2010 Jun 1;184(11):6537-44
pubmed: 20435929
J Epidemiol Glob Health. 2013 Jun;3(2):105-17
pubmed: 23856572
Lancet Respir Med. 2017 Apr;5(4):282-290
pubmed: 28215501
Int J Tuberc Lung Dis. 2009 Jan;13(1):84-92
pubmed: 19105884
Trop Med Int Health. 2009 Feb;14(2):136-42
pubmed: 19236665
Am J Respir Crit Care Med. 2015 May 15;191(10):1176-84
pubmed: 25763458
Trials. 2008 Nov 07;9:63
pubmed: 18992133
Expert Rev Anti Infect Ther. 2005 Dec;3(6):981-93
pubmed: 16307510
Am J Epidemiol. 2016 Jan 15;183(2):156-66
pubmed: 26646292